Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Neoplasm Metastasis 8Rectal Neoplasms 6Colonic Neoplasms 4Uveal Melanoma 3Stomach Neoplasms 2Neoplasms 2Recurrence 1Pancreatic Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Tract Neoplasms 1Advanced Colorectal Cancer 1

Interventions

Cisplatin 109Radiotherapy 100Fluorouracil 90Paclitaxel 75Oxaliplatin 63Docetaxel 56Carboplatin 55Irinotecan 41Esophagectomy 41Leucovorin 40Capecitabine 39Surgical Procedures, Operative 36Radiation 36Drug Therapy 31Neoadjuvant Therapy 25Chemoradiotherapy 18Cetuximab 18S 1 (combination) 17pembrolizumab 16camrelizumab 16Nivolumab 15Magnetic Resonance Spectroscopy 15Bevacizumab 15Blood Specimen Collection 14Surveys and Questionnaires 12Radiotherapy, Intensity-Modulated 12Immunotherapy 11Epirubicin 11Biopsy 11Trastuzumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Neoplasms × aflibercept × Clear all
NCT01747551 2020-02-10

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
64 enrolled 11 charts
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡